Rocket Pharmaceuticals Adopts Severance Program; CEO & Exec Agreements

What Happened
Rocket Pharmaceuticals, Inc. announced on August 21, 2026 (filed 8-K Aug 27, 2026) that its Board adopted a new Rocket Pharmaceuticals, Inc. Severance and Change in Control Program covering eligible U.S. employees and that the company entered new or amended executive employment agreements with CEO Gaurav Shah, M.D., General Counsel & Chief Corporate Officer Martin Wilson, and COO Christopher Stevens. The Program and the agreements specify severance pay, COBRA/healthcare continuation, and bonus treatment for qualifying terminations, including special provisions for terminations tied to a change in control.

Key Details

• Program adopted Aug 21, 2026; full text to be filed as an exhibit to the company’s Form 10-Q for the quarter ended Sept 30, 2026.
• Coverage: all U.S. employees not already covered by another severance arrangement; 1-year service required to receive non-change-in-control severance. Severance contingent on execution and non-revocation of a release of claims.
• CEO Gaurav Shah: base salary $674,856; target bonus 60% of base. Severance if terminated without Cause or for Good Reason: 15 months base salary + 15 months COBRA (non-CIC); within 12 months after a Change in Control: 18 months base salary, 100% target bonus for year of termination, prorated bonus, and 18 months COBRA.
• Martin Wilson: base salary $547,313; target bonus 45% of base. Severance if terminated without Cause or for Good Reason: 12 months base salary + 12 months COBRA (non-CIC); enhanced treatment applies if termination occurs within 3 months prior to or 12 months following a Change in Control.
• Christopher Stevens (COO): amendment provides 12 months base salary plus prior-year bonus and 12 months COBRA if terminated without Cause or for Good Reason; enhanced Change in Control treatment provides a full-year base salary and target/prorated bonuses plus 12 months COBRA.

Why It Matters
For investors, this filing signals formalized severance and change-in-control protections that can affect cash obligations and executive retention costs. The Program creates standardized payout tiers (from two months for junior staff up to 18 months for the CEO around a change in control) and could lead to sizable lump-sum payments if multiple qualifying terminations occur or if a change-in-control triggers enhanced payments. The agreements also show the company’s approach to retaining key executives (salary and target bonus levels for the CEO and top officers) and clarify the contractual terms that would govern payouts in various termination scenarios.